Structural patterns for antitumor drugs, evidenced by means of a molecular interaction field (MIF) approach using grid independent descriptors (GRIND). resembled closely those of a previous independent pharmacological classification based on their antitumor mechanism of action. For topoisomerase II inhibitors, antimitotic agents and DNA antimetabolites, systematic structural patterns were evidenced by MIF and the structural features of "outliers" in these classes corresponded to peculiar pharmacological mechanisms of action supported by literature evidences. Alkylating agents and DNA/RNA antimetabolites, interacting with a large variety of targets by different molecular mechanisms. did not exhibit clustering in the structure-based MIF approach. Moreover MIFS were able to point out similarities between drugs which. in spite of apparent dramatic differences in chemical structure, exhibit the same pharmacological behaviour.

Structure-based Rationalization of Antitumor Drugs Mechanism of Action by a MIF Approach

CONDORELLI, Daniele Filippo;FORTUNA, COSIMO GIANLUCA;MUSUMARRA, Giuseppe
2004-01-01

Abstract

Structural patterns for antitumor drugs, evidenced by means of a molecular interaction field (MIF) approach using grid independent descriptors (GRIND). resembled closely those of a previous independent pharmacological classification based on their antitumor mechanism of action. For topoisomerase II inhibitors, antimitotic agents and DNA antimetabolites, systematic structural patterns were evidenced by MIF and the structural features of "outliers" in these classes corresponded to peculiar pharmacological mechanisms of action supported by literature evidences. Alkylating agents and DNA/RNA antimetabolites, interacting with a large variety of targets by different molecular mechanisms. did not exhibit clustering in the structure-based MIF approach. Moreover MIFS were able to point out similarities between drugs which. in spite of apparent dramatic differences in chemical structure, exhibit the same pharmacological behaviour.
2004
antitumor drugs; chemiformatics; 3D-QSAR
File in questo prodotto:
File Dimensione Formato  
EJMedC04.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 382.15 kB
Formato Adobe PDF
382.15 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/25294
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
social impact